Recombinant Rabbit Potassium voltage-gated channel subfamily A member 5 (KCNA5)

What is KCNA5 and what is its physiological significance?

KCNA5, also known as Kv1.5, belongs to the shaker-related subfamily of voltage-gated potassium channels. It consists of six membrane-spanning domains with a shaker-type repeat in the fourth segment . As a delayed rectifier class channel, KCNA5 plays a crucial role in restoring the resting membrane potential of neurons and cardiac muscle cells following depolarization .

In cardiac physiology, human KCNA5 conducts the ultra-rapid delayed rectifier potassium current (IKur) and serves as a key determinant of the atrial action potential . The channel's importance extends beyond cardiac function, as KCNA5 also regulates vascular tone in smooth muscle cells and influences cell proliferation in various tissues .

Rabbit KCNA5, particularly from vascular smooth muscle, shares structural and functional similarities with other mammalian KCNA5 channels but possesses unique properties that make it valuable for comparative studies of channel function across species .

How does rabbit KCNA5 compare structurally to KCNA5 from other species?

Rabbit KCNA5 from vascular smooth muscle (specifically portal vein) encodes a protein of 598 amino acid residues with the characteristic features of the Kv superfamily of potassium channels . Interestingly, rabbit portal vein KCNA5 (RPVKv1.5) is identical in amino acid sequence to rabbit cardiac Kv1.5, despite having six silent mutations in the nucleotide sequence .

When compared to KCNA5 channels from other species, rabbit KCNA5 shows significant homology but with notable differences. The amino acid sequence of RPVKv1.5 is similar, but not identical, to Kv1.5 channels from:

• Canine colonic smooth muscle

• Human ventricular muscle

• Human pancreas

The differences primarily occur in three regions:

• The cytoplasmic N-terminal region

• The cytoplasmic C-terminal region

• The S1-S2 linker region

These structural variations likely contribute to species-specific differences in channel function, pharmacology, and regulation, highlighting the importance of species consideration in KCNA5 research.

What are the key regulatory sites in rabbit KCNA5?

Rabbit KCNA5 contains several consensus phosphorylation sites that are critical for channel regulation . These post-translational modification sites provide mechanisms for dynamic control of channel activity in response to various physiological stimuli.

The key regulatory sites in rabbit KCNA5 include:

• PKA (Protein Kinase A) phosphorylation sites:

  • 539RKAS542 near the C-terminus

  • 562RRGS565 near the C-terminus

• PKC (Protein Kinase C) phosphorylation sites:

  • 47RGCSARR53 near the N-terminus

  • 545KASLCK550 near the C-terminus

These phosphorylation sites suggest that rabbit KCNA5 activity is modulated by both sympathetic (via PKA) and other signaling pathways (via PKC). Researchers investigating channel regulation should consider these sites when designing experiments to study how phosphorylation affects channel properties such as voltage dependence, kinetics, and trafficking.

What are the optimal methods for cloning recombinant rabbit KCNA5?

The cloning of recombinant rabbit KCNA5 requires careful consideration of tissue source, RNA extraction techniques, and PCR strategies. Based on established protocols, the following methodological approach has proven effective:

• Tissue Selection and Preparation:

  • Portal vein tissue from rabbits (2-2.5 kg) provides a reliable source

  • Careful removal of adventitia and endothelium is critical to ensure myocyte-specific mRNA

  • Tissue should be promptly processed to minimize RNA degradation

• mRNA Isolation:

  • Extraction of total RNA from homogenized tissue using a denaturing solution

  • Isolation of poly(A)+ RNA from total RNA using a mRNA PolyATract system

  • Approximately 9 μg of mRNA can be obtained from ten rabbit portal veins

• RT-PCR Strategy:

  • Conversion of poly(A)+ RNA (0.5 μg) to cDNA using reverse transcriptase with oligo(dT) primers

  • PCR amplification using primers based on known sequences (e.g., rabbit cardiac Kv1.5)

  • Recommended PCR conditions: 35 cycles of 98°C for 30s, 60°C for 30s, and 72°C for 2 min

  • Incorporation of appropriate restriction sites (e.g., EcoRI, BamHI) in primers to facilitate subcloning

• Sequence Verification and Correction:

  • Subcloning of amplified products into appropriate vectors (e.g., pBluescript II SK(+))

  • Sequence determination of multiple full-length PCR clones

  • Identification and correction of PCR-induced mutations by generating a composite construct using restriction enzymes

This systematic approach ensures the generation of an accurate and functional rabbit KCNA5 clone suitable for expression studies and functional characterization.

How do the electrophysiological properties of recombinant rabbit KCNA5 compare with native channels?

Comparative electrophysiological analysis reveals both similarities and differences between recombinant rabbit KCNA5 and native Kv1.5 channels in rabbit portal vein myocytes. These comparisons provide important insights into how expression systems influence channel behavior.

Current Density Comparison:

The recombinant channels expressed in L cells demonstrate significantly higher current density than native channels (p < 0.05), likely reflecting higher expression levels in the heterologous system .

Activation Kinetics Comparison:

Deactivation Kinetics Comparison:

These data indicate that:

• Activation and deactivation of both native KDR currents and L cell-expressed RPVKv1.5 follow double exponential kinetics

• Native KDR channels and L cell-expressed RPVKv1.5 display similar time constants of activation and deactivation

• The same channel expressed in different cell types (L cells vs. HEK293 cells) exhibits different kinetic properties

These findings highlight the importance of considering the expression system when interpreting electrophysiological data from recombinant channels.

What role does KCNA5 dysfunction play in pathophysiological conditions?

KCNA5 dysfunction has been implicated in various pathophysiological conditions, making it an important target for therapeutic intervention. Research has identified several disease states associated with altered KCNA5 function or expression:

• Atrial Fibrillation (AF):

  • KCNA5 conducts the ultra-rapid delayed rectifier potassium current (IKur) in atria

  • Alterations in KCNA5 function contribute to abnormal atrial action potential duration

  • KCNA5 represents a promising target for AF-selective therapy due to its predominant atrial expression

• Pulmonary Arterial Hypertension (PAH):

  • 17 single-nucleotide polymorphisms of the KCNA5 gene have been identified in PAH patients

  • These genetic variations may contribute to KCNA5 downregulation, leading to increased vascular tone

  • In intrauterine growth retardation, decreased KCNA5 expression coupled with increased tyrosine-phosphorylation promotes pulmonary artery smooth muscle cell proliferation

  • This proliferative effect results in pulmonary arterial wall thickening characteristic of PAH

• Neoplastic Conditions:

  • KCNA5 is associated with Src family protein tyrosine kinases in astrocytes

  • This association plays a role in astrocyte proliferation

  • The connection between KCNA5 and cell proliferation has prompted numerous tumor-related studies

  • Research indicates that Caveolin-1 facilitates KCNA5 expression, promoting breast cancer progression

Understanding these pathophysiological roles provides a foundation for developing targeted therapeutic strategies that modulate KCNA5 function in a disease-specific manner.

What approaches are effective for studying KCNA5 channel pharmacology?

Investigating KCNA5 channel pharmacology requires robust experimental approaches that allow for precise measurement of channel function and drug interactions. Several methodological strategies have proven effective:

• Electrophysiological Techniques:

  • Whole-cell patch-clamp recordings provide comprehensive assessment of channel function

  • Cell-attached and inside-out patch configurations offer insights into single-channel properties

  • Key recording solutions for whole-cell voltage clamp:

    • Bath solution (mM): 120 NaCl, 3 NaHCO3, 4.2 KCl, 1.2 KH2PO4, 0.5 MgCl2, 10 glucose, 1.8 CaCl2, 10 Hepes (pH 7.4)

    • Pipette solution (mM): 110 potassium gluconate, 30 KCl, 0.5 MgCl2, 5 Hepes, 5 Na2ATP, 1 GTP, 10 BAPTA

• Heterologous Expression Systems:

  • L cells and HEK293 cells provide reliable platforms for recombinant KCNA5 expression

  • Co-transfection with green fluorescent protein (GFP) facilitates identification of transfected cells

  • Lipofectin-mediated transfection has been optimized for efficient uptake and expression

• Peptide Inhibitor Studies:

  • Peptide inhibitors offer a targeted approach to modulating KCNA5 function

  • Rational drug design can improve peptide affinity and selectivity for KCNA5

  • In silico docking experiments guide targeted modification of amino acid sequences

• Comparative Pharmacology:

  • Comparing drug effects across species and expression systems reveals important insights

  • Testing compounds on both recombinant channels and native tissues allows assessment of specificity

  • Pharmacological differences between expression systems should be carefully considered when interpreting results

These approaches provide a comprehensive toolkit for researchers investigating KCNA5 pharmacology, facilitating the development of novel therapeutic agents for conditions involving KCNA5 dysfunction.

What immunological techniques are effective for detecting rabbit KCNA5?

Immunological detection of rabbit KCNA5 requires careful selection of antibodies and optimization of experimental protocols. Based on established research methods, the following approaches have proven effective:

• Antibody Selection:

  • Polyclonal antibodies raised against C-terminal epitopes of KCNA5 show good specificity

  • Antibodies raised against mouse KCNA5 C-terminal epitopes cross-react effectively with rabbit KCNA5

  • Commercial options include rabbit polyclonal antibodies with concentration of 0.25 mg/ml purified IgG

• Immunocytochemistry Protocol:

  • Freshly dispersed rabbit portal vein cells should be allowed to settle and adhere to acid-washed coverslips

  • Cell permeabilization using 0.1% Triton X-100 in Pipes-buffered solution for 5 minutes

  • Incubation with primary antibody at 1:70 dilution overnight at 4°C

  • Secondary antibody incubation (goat anti-rabbit IgG conjugated with TRITC, CY3, or FITC) at 1:100 dilution for 1 hour

  • Washing steps using Pipes solution containing 0.5% bovine serum albumin

• Western Blot Applications:

  • KCNA5 antibodies validated for Western blot can detect the approximately 67 kDa KCNA5 protein

  • Effective for materials from rodent and human tissues

  • Can be used to quantify changes in KCNA5 expression under various experimental conditions

• Controls and Validation:

  • Control cells exposed to secondary antibody alone are essential to assess non-specific binding

  • Multiple biological replicates (e.g., preparations from different rabbits) ensure reliability

  • Observation of at least 15 cells per treatment group is recommended for representative results

These techniques provide researchers with reliable tools for investigating KCNA5 expression and localization in rabbit tissues, facilitating studies of channel regulation and trafficking.

What are the optimal conditions for expressing recombinant rabbit KCNA5 in mammalian cells?

Successful expression of recombinant rabbit KCNA5 in mammalian cells requires optimization of several key parameters. The following conditions have been established to achieve efficient expression and functional channel activity:

• Expression Vector Selection:

  • Subcloning of KCNA5 cDNA into mammalian expression vectors such as pcDNA3

  • Incorporation of appropriate restriction sites (e.g., KpnI and BamHI) for directional cloning

  • Co-expression with reporter genes (e.g., GFP) to identify transfected cells

• Cell Line Selection:

  • Mouse connective tissue L cells and human embryonic kidney (HEK293) cells both support robust KCNA5 expression

  • Expression in different cell lines yields channels with subtly different electrophysiological properties

  • Cell choice should be guided by the specific research question and desired channel characteristics

• Transfection Protocol:

  • Lipofectin-mediated transfection optimized for KCNA5 expression

  • For 80% confluent cultures (30 mm dish):

    • 3 μg of DNA and 20 μl of lipofectin per dish

    • 5-hour incubation in serum-free medium

    • Restoration of standard culture medium overnight before splitting cells

  • Transfected cells should be used within 72 hours for optimal expression

• Culture Conditions:

  • Maintenance in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum

  • Incubation under 10% CO2 atmosphere

  • Regular passaging every 5-6 days by mechanical disruption

  • Transfer to acid-washed coverslips for electrical recordings

• Expression Verification:

  • Successful transfection identified by GFP fluorescence

  • Functional expression confirmed by whole-cell voltage clamp recordings

  • 100% of GFP-positive cells should display time-dependent outward K+ current

  • Control cells (transfected with GFP alone or untransfected) should not display time-dependent outward K+ current

These optimized conditions provide a reliable framework for expressing functional recombinant rabbit KCNA5 channels in mammalian cells, facilitating detailed electrophysiological and pharmacological investigations.

What electrophysiological protocols are most informative for characterizing KCNA5 function?

Comprehensive characterization of KCNA5 function requires carefully designed electrophysiological protocols that reveal the channel's biophysical properties. The following experimental approaches provide valuable insights into KCNA5 behavior:

• Voltage-Dependent Activation:

  • Holding potential of -60 mV

  • Series of test pulses between -80 and +30 mV

  • Analysis of end-pulse currents and tail currents

  • Calculation of current density (pA/pF) to normalize for cell size

  • Fitting activation kinetics with double exponential functions to extract fast and slow time constants

• Deactivation Kinetics:

  • Repolarization to -50 mV following activating pulses

  • Recording of tail currents during repolarization

  • Fitting with double exponential functions to determine fast and slow deactivation time constants

  • Comparison across different expression systems to assess context-dependent properties

• Single-Channel Recordings:

  • Cell-attached patch configuration for physiological assessment

  • Inside-out patch configuration for investigating cytoplasmic modulators

  • Standard solutions for cell-attached recordings:

    • Pipette solution (mM): 140 KCl, 1 CaCl2, 1 MgCl2, 5.5 glucose, 10 Hepes (pH 7.4)

    • Bath solution (mM): 140 KCl, 1 MgCl2, 5.5 glucose, 10 Hepes (pH 7.4), nominally Ca2+ free

  • For asymmetrical K+ conditions: 5.4 mM KCl in pipette with equimolar NaCl substitution

• Pharmacological Characterization:

  • Application of known K+ channel blockers (e.g., 4-AP)

  • Dose-response relationships to determine potency (EC50/IC50 values)

  • Comparison of pharmacological profiles between recombinant and native channels

  • Assessment of peptide inhibitors designed through rational drug design approaches

• Phosphorylation Studies:

  • Investigation of channel modulation at PKA and PKC consensus sites

  • Application of kinase activators or inhibitors to assess functional impact

  • Site-directed mutagenesis of phosphorylation sites to determine their functional significance

These protocols provide a comprehensive framework for functional characterization of KCNA5 channels, enabling detailed comparison between recombinant and native channels as well as assessment of physiological and pharmacological modulators.